Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2008.

Vanda reported research and development (R&D) expenses in the third quarter of 2008 of $3.8 million, compared to $5.5 million in the second quarter of 2008 and $13.9 million in the third quarter of 2007. The decrease in R&D expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon (VEC-162) chronic primary insomnia clinical trial for which Vanda announced top-line results in June of 2008. The decrease in R&D expenses in the third quarter of 2008 relative to the third quarter of 2007 is attributable to lower clinical trial costs in 2008 compared to costs from trials conducted in 2007, and the $5.0 million milestone charge recorded in the third quarter of 2007 resulting from the submission of the New Drug Application (NDA) for iloperidone.

Net loss was $10.9 million for the third quarter of 2008, compared to $13.5 million for the second quarter of 2008 and $21.9 million for the third quarter of 2007. Net loss per common share for the third quarter of 2008 was $0.41, compared to $0.51 for the second quarter of 2008 and $0.82 for the third quarter of 2007.

As of September 30, 2008, Vanda's cash, cash equivalents, and marketable securities totaled approximately $51.7 million. As of September 30, 2008, Vanda had a total of approximately 26.7 million shares of common stock outstanding.

OPERATIO
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 2015 The surging prevalence of ... fuelled social media growth, with over 50% of ... social networking. Insurance companies are making use of ... and promote a diversity of their services and ... exploiting social networking services as part of sales ...
(Date:3/25/2015)... , March 25, 2015 Accelovance, a therapeutically ... finalist for "Best Contract Research Organization" at the upcoming ... Vaccine Congress. This is the eighth ... for the award, winning for "Best Contract Research Organization" ... Recommended" distinction in 2013. "We,re excited to ...
(Date:3/25/2015)... 2015  Point-of-Care Partners, a leading health information ... launched the ePrescribing State Law Capsule -- a ... regulatory requirements in all 50 states and DC.  ... to change rapidly, so we have evolved our ... ultimately patients, need," said Tony Schueth , ...
(Date:3/25/2015)... 2015 Researchers at Ancon Medical ... that will enable broader and less invasive screening ... a simple breath screen. The Minnesota-based medical device ... and Drug Administration (FDA) approval process and is ... Nanoparticle Biomarker Tagging device. , Ancon Medicals nanoparticle ...
Breaking Biology Technology:Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... ... and cytokine-related research tips and information. , ... Piscataway, NJ (PRWEB) May 20, 2010 -- ... the world’s leading interferon expert for life science researchers, has launched a revamped ...
... , CAMBRIDGE, Mass. , May 19 Idenix Pharmaceuticals, Inc. (Nasdaq: ... the 2010 Citi Annual Global Health Care Conference on Wednesday, May 26, 2010 ... New York City and at the Jefferies 2010 Global Life Sciences Conference on ... Hyatt hotel, New York City . , ...
... May 19, 2010 Amsterdam Molecular,Therapeutics (EuroNext Amsterdam: AMT), ... non-audited business update in compliance with,the EU transparency directive. This report ... 2010. , , Q1 2010 Highlights, ... - Dossier validated by EMA on January 20, 2010, ...
Cached Biology Technology:Web Resource for Interferon Research 2Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 2AMT Provides Business Update for the First Quarter 2010 2AMT Provides Business Update for the First Quarter 2010 3
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... A joint study published in Cell by ... for Research in Biomedicine (IRB Barcelona) and the Institute ... Dolf Weijers at the University of Wageningen, in the ... called auxins activate multiple vital plant functions through various ...
... This news release is available in German . ... the death of thousands of neurons in the brain. Nerve growth ... of the neurons; however, clinical tests with GDNF have not yielded ... Neurobiology in Martinsried and their colleagues have now succeeded in demonstrating ...
... of Vitamin A used by teenagers to combat acne might ... an international team of researchers have found that it may ... with autoimmune disorders or those who have received transplants. This ... Journal of Leukocyte Biology . "The ...
Cached Biology News:Scientists unveil a molecular mechanism that controls plant growth and development 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3Vitamin A used in acne medicines may help autoimmune and transplant patients 2
...
... The new IKATUBE ULTRA TURRAX Tube Disperser ... closed homogenizing system. It offers a cleaner, safer, ... IKATUBE system processes sample volumes from 2 to ... sample type, researchers can choose one of 4 ...
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
Biology Products: